Last Updated : October 28, 2024
Details
Generic Name:
daridorexant
Project Status:
Pending
Therapeutic Area:
Insomnia
Manufacturer:
Idorsia Pharmaceuticals Canada Ltd.
Call for patient/clinician input open:
Brand Name:
Quviviq
Project Line:
Reimbursement Review
Project Number:
SR0862-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of insomnia in adults diagnosed according to the most recent version of the Diagnostic and Statistical Manual of Mental Disorders (DSM) referring to chronic insomnia disorder (CID).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For the management of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : October 28, 2024